An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Eli Lilly and Company has learned a lot about what it takes to fail in Alzheimer’s disease drug development and applied those lessons to its next-generation anti-amyloid antibody donanemab, CEO David Ricks said on the second day of the J.P. Morgan Healthcare Conference. Ricks described how the company used what it learned to design the Phase II TRAILBLAZER clinical trials of donanemab for success, as seen in positive top-line results from the first study, which were reported on the first day of the virtual meeting.